Helicobacter pylori infection: old and new

S Diaconu, A Predescu, A Moldoveanu, C S Pop, C Fierbințeanu-Braticevici, S Diaconu, A Predescu, A Moldoveanu, C S Pop, C Fierbințeanu-Braticevici

Abstract

Helicobacter pylori is a spiral-shaped bacterium that grows in the digestive tract and may be present in more than half of the world's population. The clinical features of Helicobacter pylori range from asymptomatic gastritis to gastrointestinal malignancy. Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell marginal zone lymphoma and Helicobacter pylori has been detected in more than 75% of the patients with MALT lymphoma. Many tests for the detection of Helicobacter pylori are available, including antibody tests, urea breath tests, stool antigen tests and endoscopic biopsies. The eradication of Helicobacter pylori usually prevents the return of ulcers and ulcer complications even after appropriate medications such as PPIs are stopped. The eradication of Helicobacter pylori is important in the treatment of the rare condition of the stomach known as MALT lymphoma. The treatment of Helicobacter pylori to prevent stomach cancer is controversial. Confirmation of eradication is recommended in associated ulcers, persistent dyspepsia despite a test-and-treat approach, MALT lymphoma, and previous treatment for early-stage gastric cancer. The urea breath test and stool antigen test can be used to confirm the eradication and should be performed at least 4 weeks after the completion of therapy. Several diseases have been reported to be associated with Helicobacter pylori infection, including hematologic diseases, such as ITP, idiopathic iron deficiency anemia and vitamin B12 deficiency. There is a positive trend in the association between Helicobacter pylori infection and neurodegenerative disorders and new data showed a reduced risk of death due to stroke and lung cancer but an increased risk of preeclampsia in infected women, which requires further investigations.

Keywords: Helicobacter pylori; gastric carcinoma; gastritis; proton pump inhibitor; ulcer.

Figures

Fig. 1
Fig. 1
Natural history of infection with Helicobacter pylori
Fig. 2
Fig. 2
Algorithm for first-line treatment [,]
Fig. 3
Fig. 3
Algorithm for second-line treatment []

References

    1. Goh K-L, Chan W-K, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori Infection and Public Health Implications. Helicobacter. 2011;16(0-1):1–9.
    1. Ieni A, Barresi V, Rigoli L, Fedele F, Tuccari G, Caruso RA. Morphological and Cellular Features of Innate Immune Reaction in Helicobacter pylori Gastritis: A Brief Review. International Journal of Molecular Sciences. 2016;17(1):109.
    1. American College of Physicians (2003- ) MKSAP 17: medical knowledge self-assessment program. Philadelphia, Pa.: American College of Physicians; 2015.
    1. Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World Journal of Gastroenterology: WJG. 2014;20(18):5461–5473.
    1. Liou J-M, et al. Association of H. pylori and Gastric Cancer in Observational Studies. In: Suzuki H, ed. Helicobacter pylori. New York, NY: Springer Berlin Heidelberg; 2016. pp. 183–188.
    1. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report. Gut. 2016
    1. Del Zompo F, Ojetti V, Feliciani D, et al. Helicobacter pylori infection is associated with high methane production during lactulose breath test. European Review for Medical and Pharmacological Sciences. 2016;20(16):3452–3456.
    1. Enko D, Kriegshauser G. Functional 13C-urea and glucose hydrogen/ methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem. 2017;50(1-2):46–49.
    1. Fallah S, Ahmadi R, Moradi N, Fadaei R, Sezavar SH, Seifi M. Helicobacter pylori infection and iron deficiency in patients with coronary artery disease. Cell Mol Biol (Noisy-le-grand) 2016;62(8):8–14.
    1. Goni E, Franceschi F. Helicobacter pylori and extragastric diseases. Helicobacter. 2016;21(Suppl 1):45–48.
    1. Bazmamoun H, Rafeey M, Nikpouri M, Ghergherehchi R. Helicobacter Pylori Infection in Children with Type 1 Diabetes Mellitus: A Case-Control Study. J Res Health Sci. 2016 ;16(2):68–71.
    1. Di Simone N, Tersigni C, Cardaropoli S, et al. Helicobacter pylori infection contributes to placental impairment in preeclampsia: basic and clinical evidences. Helicobacter. 2016
    1. Bonfigli AR, Boemi M, Festa R, et al. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2016 ;26(10):893–898.
    1. Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter. 2017 ;22(1)
    1. Upala S, Jaruvongvanich V, Riangwiwat T, Jaruvongvanich S, Sanguankeo A. Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta-analysis. Journal of Digestive Diseases. 2016 ;17(7):433–440.
    1. von Arnim U, Wex T, Link A, et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016 ;43(7):825–830.
    1. Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Annals of Translational Medicine. 2015 ;3(1):10.
    1. Wang Y-K, Kuo F-C, Liu C-J, et al. Diagnosis of Helicobacter pylori infection: Current options and developments. World Journal of Gastroenterology: WJG. 2015 ;21(40):11221–11235.
    1. Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol. 2003 ;119(3):403–412.
    1. Boldt MS, Pereira RD, Barbosa AJA. Histological identification of H. pylori stained by hematoxylin-eosin and Giemsa: review for quality control. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2015 ;51:108–112.
    1. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol. 2001 ;15(9):591–598.
    1. Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 ;386(10002):1457–1464.
    1. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology. 2017 ;112(2):212–239.
    1. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016 ;43(4):514–533.
    1. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016 ;65(1):9–18.
    1. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 ;8(2):79–88.
    1. Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013 ;18(Suppl 1):44–51.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren